624 related articles for article (PubMed ID: 16374859)
1. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
Khound R; Taher J; Baker C; Adeli K; Su Q
Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2252-2259. PubMed ID: 29074588
[TBL] [Abstract][Full Text] [Related]
3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
Gupta NA; Mells J; Dunham RM; Grakoui A; Handy J; Saxena NK; Anania FA
Hepatology; 2010 May; 51(5):1584-92. PubMed ID: 20225248
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
6. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice.
Park HJ; DiNatale DA; Chung MY; Park YK; Lee JY; Koo SI; O'Connor M; Manautou JE; Bruno RS
J Nutr Biochem; 2011 Apr; 22(4):393-400. PubMed ID: 20655714
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.
Lee J; Hong SW; Chae SW; Kim DH; Choi JH; Bae JC; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Kim SW; Lee WY
PLoS One; 2012; 7(2):e31394. PubMed ID: 22363635
[TBL] [Abstract][Full Text] [Related]
10. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Sutariya B; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Can J Physiol Pharmacol; 2018 Jun; 96(6):587-596. PubMed ID: 29406832
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
[TBL] [Abstract][Full Text] [Related]
12. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.
Perfield JW; Ortinau LC; Pickering RT; Ruebel ML; Meers GM; Rector RS
J Obes; 2013; 2013():296537. PubMed ID: 23401753
[TBL] [Abstract][Full Text] [Related]
13. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
14. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.
Xu F; Li Z; Zheng X; Liu H; Liang H; Xu H; Chen Z; Zeng K; Weng J
Diabetes; 2014 Nov; 63(11):3637-46. PubMed ID: 24947350
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
Lee YS; Park MS; Choung JS; Kim SS; Oh HH; Choi CS; Ha SY; Kang Y; Kim Y; Jun HS
Diabetologia; 2012 Sep; 55(9):2456-68. PubMed ID: 22722451
[TBL] [Abstract][Full Text] [Related]
17. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Wang L; Guo F; Wei S; Zhao R
Peptides; 2011 Jun; 32(6):1313-9. PubMed ID: 21453734
[TBL] [Abstract][Full Text] [Related]
18. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
19. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
20. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
